Cervical Cancer ScreeningNCT07545525
HPV Testing as a Prevention of Cervical Dysplasia and Cancer Before Planned Subtotal Hysterectomy
An observational study of Cervical Cancer Screening and Human Papilloma Virus (HPV), run by General University Hospital, Prague.
Trial summary
Patients indicated for subtotal hysterectomy will be tested for High risk HPV and if the result is positive will undergo expert colposcopy and conisation if not indicated otherwise at the time of subtotal hysterectomy Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Cervical Cancer Screening, Human Papilloma Virus (HPV)
- How many people
- 300 participants
- Where
- No sites listed yet
- Study dates
- Apr 2026to Apr 2029
- How long will I take part?
- 6 Months
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Women over 18 years old indicated for subtotal hysterectomy surgery mostly due to pelvic organ prolapse
Who may be able to join
- age over 18
- indication for subtotal hysterectomy
- consent to provide conisation in case the HPV test result is positive
Who cannot join
- negative HPV test in the last 3 years
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: HPV Testing as a Prevention of Cervical Dysplasia and Cervical Cancer Before Planned Subtotal Hysterectomy
Patients indicated for subtotal hysterectomy will be tested for High risk HPV and if the result is positive will undergo expert colposcopy and conisation if not indicated otherwise at the time of subtotal hysterectomy
What is being measured
The primary outcome is the main question the study is designed to answer.
Benefit of addition of HPV DNA testing before subtotal hysterectomy
Prevalence of HPV positivity in the tested cohort (patients indicated for subtotal hysterectomy).
Prevalence of HPV (other than HPV 16 and 18) positivity in the tested cohort (patients indicated for subtotal hysterectomy).
Prevalence of abnormal oncological cytology result and correlation to HPV result in the tested cohort (patients indicated for subtotal hysterectomy).
Prevalence of cervical intraepithelial leasions in patients who underwent cone biopsy with the subtotal hysterectomy.
Prevalence of high grade cervical intraepithelial leasions in patients who underwent cone biopsy with the subtotal hysterectomy.
Rate of HPV negativity 6 months after cone biopsy.
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2026
- Study startApr 2026 (estimated)
- Primary completionApr 2028 (estimated)
- Study completionApr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical Cancer ScreeningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- General University Hospital, Prague
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tomáš Fučík, General University Hospital, Prague
- Investigators
- Lukáš Dostálek, M.D., Study director, General Universty Hospital in Prague, Czech Republic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07545525
- Sponsor's protocol ID
- 032026
- Status last verified
- Apr 2026
- First submitted
- 14 Apr 2026
- Last updated
- 22 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided